Source:
http://www.bamclinic.org/feeds/posts/default?alt=rss

* Shire (Stuttgart: A0MMAG – news) to pay $13 mln upfront, plus milestones

* Sangamo shares rise more than 25 percent (Adds analyst comment, share price)

Feb 1 (Reuters) – Pharmaceutical company Shire said on Wednesday it would collaborate with Sangamo BioSciences (Hamburg: GBY.HM – news) to develop treatments for hemophilia and other inherited diseases based on Sangamo's gene regulation and modification technology.

The news, seen as a vote of confidence in Sangamo's experimental gene-disrupting technique, sent shares of the Richmond (NZSE: RHD.NZ – news) , California-based company up more than 25 percent.

Shire is buying the rights to the U.S. company's proprietary technology to target four genes, which the company said it hoped could lead to therapies for haemophilia A and B. Shire also acquired the right to designate three additional gene targets.

Sylvie Grégoire, president of Shire's Human Genetic Therapies business, said: “While still early in the clinical development process, this DNA-binding protein technology is aligned with our focus of developing new treatments.”

The British company is paying Sangamo $13 million in an upfront payment, followed by development and commercial payments and royalties on product sales.

After the deal was announced, Piper Jaffray (Berlin: PJR.BE – news) upgraded Sangamo to “neutral” from “underweight,” and raised its price target on the shares to $4 from $2.

Shares of Sangamo were up 92 cents at $4.37 in midday trading on Nasdaq (Nasdaq: ^NDX – news) .

Genetic disease are an important therapeutic area for Shire, and the group has found success with drugs to treat the rare Gaucher's and Fabry's diseases. (Reporting by Paul Sandle and Deena Beasley. Editing by Gunna Dickson)

Continued here:
UPDATE 2-Shire partners Sangamo in gene therapy for hemophilia

www.youtube.com/watch?v=0nk80YTyeT8

Read more:
Entering into the clinic with an intracerebral gene therapy product / Karen Aiach, Project Manager, – Video

www.youtube.com/watch?v=WCfIppT5FEo

See the article here:
Apes Trailer/Gene Therapy – Video

See the article here:
Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in …

www.youtube.com/watch?v=zaE1v8k-CHs

Read the rest here:
Promising gene therapy treats Leukemia – Video

Link:
Fibrocell Science, Inc. Announces Recognition for LAVIV™ (azficel-T) at The 2012 Cell & Gene Therapy Forum, Washington …

SAN DIEGO, Jan. 30, 2012 /PRNewswire/ – Cardium
Therapeutics (NYSE Amex: CXM) today reported on new insights
and confirmatory preclinical study results on the Generx
(Ad5FGF-4) angiogenic therapy product candidate based on the
Company's sponsored research conducted at Emory
University.  The findings, which provide further support
for the apparent safety and effectiveness of Generx as a
potential one-time non-surgical approach to the treatment of
coronary heart disease, are being presented at the Phacilitate
Annual Gene and Cell Therapy Forum held January 30 – February
1, 2012 in Washington, DC.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The recent preclinical findings demonstrate that induced
transient ischemia, using a standard angioplasty balloon
catheter, combined with the intracoronary co-infusion of
nitroglycerin, substantially enhanced adenovector-mediated gene
delivery to the heart.  These findings have been
incorporated into the protocol for the planned 100-patient
Generx (Ad5FGF-4) ASPIRE Phase 3 registration study which, as
previously reported, is expected be initiated in the first
quarter 2012.  The YouTube video “Cardium Generx
Cardio-Chant” provides an overview of the Company's Generx
(Ad5FGF-4) product candidate, at http://www.youtube.com/watch?v=pjUndFhJkjM.

The new data underscore the expected benefit of Cardium's
improved adenovector administration methods that combine
non-surgical, percutaneous balloon catheter-based delivery with
transiently-induced ischemia and nitroglycerin to enhance
uptake leading to improved microvascular circulation in the
heart. By increasing cell transfection efficiency, this
modified approach allows for effectively obtaining additional
targeted expression of growth factors within the ischemic
heart, where the resulting angiogenesis or blood vessel growth
can bring about improved blood flow throughout the ischemic
myocardium.  Traditional interventional cardiology
approaches such as coronary artery bypass surgery (CABG) or
angioplasty and stenting (PCI), not only require invasive and
costly surgical procedures but they can only directly target
selected vulnerable spots in larger vessels that are
susceptible to treatment and reachable through mechanical
intervention.

Another important outcome of these preclinical studies was the
confirmation that intracoronary infusion of an adenovector
directly to the ischemic region of the left ventricle caused no
myocardial inflammation or any other untoward effects. These
Cardium-sponsored studies were undertaken by researchers at the
Carlyle Cardiothoracic Surgery Center at Emory University,
Atlanta.  The presentation given at the Annual Gene and
Cell Therapy Forum entitled “ASPIRE Trial: A Phase 3 Pivotal
Registration Trial Incorporating Preclinical and Clinical
Lessons Learned in the Past Decade”, is now available for
viewing on the Generx section of Cardium's website at http://www.cardiumthx.com/generx.html.

“Cardium has established the world's largest clinical database
on a DNA-based interventional cardiovascular therapeutic
derived from clinical studies in over 650 patients with
coronary artery disease that have been conducted at over 100
medical centers in the United States, South America and Western
Europe.  Our extensive preclinical and clinical studies
have also identified cardiac ischemia as a key factor for the
successful use of non-surgical DNA-based angiogenic therapy.
 The observation that myocardial ischemia is a necessary
condition for both the effective delivery and therapeutic
effectiveness of Generx is a very positive one, and has
favorable implications for the potential utility of Generx in
the treatment of coronary heart disease.  The new findings
confirming that our modified delivery procedures have the
potential to substantially improve adenovector uptake further
support the expected value of our ASPIRE Phase 3 registration
study, which employs these techniques in targeted patients with
coronary artery disease who have the potential to be best
served by our Generx angiogenic therapy,” stated Christopher J.
Reinhard, Cardium's Chairman and Chief Executive Officer.

Generx ASPIRE Clinical Study

The Company has received clearance from the Russian Ministry of
Health and Social Development to commence a Phase 3
registration study for the Company's Generx™ (alferminogene
tadenovec, Ad5FGF-4) biologic product candidate, which is
expected to begin patient enrollment in the first quarter
2012.  Generx is a new and innovative DNA-based angiogenic
therapy designed for the potential treatment of myocardial
ischemia due to coronary artery disease. The Russian Health
Authority has assigned Generx the therapeutic drug trade name
of Cardionovo™ for marketing and sales in Russia. 

This newly approved clinical study (ASPIRE) is a randomized,
controlled, parallel group, multi-center study designed to
evaluate the safety and efficacy of Cardium's Generx product
candidate using SPECT imaging to measure improvements in
microvascular cardiac perfusion following a one-time,
non-surgical, catheter-based administration of Generx DNA-based
angiogenic therapy.  As designed, the ASPIRE clinical
study is expected to enroll approximately 100 men and women
with myocardial ischemia due to coronary artery disease at up
to six leading medical centers in Moscow.  The study's
primary efficacy endpoint will be the improvement in reversible
perfusion defect size as measured by SPECT imaging.

The ASPIRE study will represent the fifth clinical study under
Generx's clinical development program that when completed will
have enrolled more than 750 patients at over 100 medical
centers throughout the U.S., Canada, South America, Western
Europe and Russia.  Based on the specified clearance for
the Russian Health Authority, with positive safety and efficacy
data from this single registration study, Cardium's Russian
sponsor and development partner, Advanced Biosciences Research,
an affiliate of the contract research organization bioRASI,
would be in a position to consider the submission of an
application for marketing and sales of Generx in the Russian
Federation, and to advance forward with applications and
submissions seeking approval for marketing and sales of Generx
in certain other countries of the Commonwealth of Independent
States, comprising former republics under the Soviet
Union.  The ASPIRE study could also provide additional
clinical evidence regarding the safety and effectiveness of
Generx that would be useful for optimizing and broadening
commercial development pathways in other industrialized
countries.

Positive results from the prior Phase 2a clinical study (Grines
et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx
improved myocardial blood flow in the ischemic region of the
hearts of men and women following a single intracoronary
infusion as measured by the objective efficacy endpoint of
SPECT imaging.  As noted in the publication, the mean
change observed in Generx-treated patients was a 4.2% absolute
reduction (which represents a 20% relative reduction) in the
reversible perfusion defect size from baseline at eight weeks
(p<0.001), while the placebo group showed only a 1.6%
absolute reduction from baseline (not significant) at eight
weeks following treatment.  The observed treatment effect
for patients receiving Generx was similar in magnitude to that
reported in the literature for patients undergoing
angioplasty/stent or revascularization procedures with
reversible perfusion defects of comparable size at one year
following these procedures.

An independent long-term prospective study published in
Circulation (Meier et al, Circ. 2007; 116:975-983) provided key
evidence indicating that men and women with more recruitable
collateral circulation have a better chance of surviving a
heart attack than patients who have less developed collateral
circulation.  This important study quantitatively
evaluated coronary collateral blood flow in 845 patients with
coronary artery disease during a 10-year follow-up period and
showed that long-term cardiac mortality was approximately 66%
lower in patients with a highly developed collateral vessel
blood supply (p=0.019).  For the first time, this study
showed the importance of collateral circulation beyond simply
the relief of angina and provided further support of the
potential for long term benefits from angiogenic therapy.

About Cardium

Cardium is focused on the acquisition and strategic development
of new and innovative bio-medical product opportunities and
businesses with the potential to address significant unmet
medical needs that have definable pathways to
commercialization, partnering and other economic
monetizations.  Cardium's current medical opportunities
portfolio, which is focused on health sciences and regenerative
medicine, includes the Tissue Repair Company, Cardium
Biologics, and the Company's in-house MedPodium Health Sciences
healthy lifestyle product platform.  Cardium's lead
commercial product Excellagen™ topical gel for advanced wound
care management, has recently received FDA clearance for
marketing and sale in the United States.  Cardium's lead
clinical development product candidate Generx® is a DNA-based
angiogenic biologic intended for the treatment of patients with
myocardial ischemia due to coronary artery disease.  In
addition, consistent with its capital-efficient business model,
Cardium continues to actively evaluate new technologies and
business opportunities.  In July 2009, Cardium completed
the sale of its InnerCool Therapies medical device business to
Royal Philips Electronics, the first asset monetization from
the Company's biomedical investment portfolio. News from
Cardium is located at www.cardiumthx.com.

Forward-Looking Statements  

Except for statements of historical fact, the matters discussed
in this press release are forward looking and reflect numerous
assumptions and involve a variety of risks and uncertainties,
many of which are beyond our control and may cause actual
results to differ materially from stated expectations. 
For example, there can be no assurance that enhancements in the
uptake of adenovectors can be successfully applied to improve
the uptake or therapeutic effects of Generx in human patients;
that Generx can be successfully advanced in clinical studies
outside of the U.S.; that results or trends observed in one
clinical study or procedure will be reproduced in subsequent
studies or procedures, or that clinical studies even if
successful will lead to product advancement or partnering; that
improvements in the formulation or use of Generx will be
commercially practicable, or that Generx could be successfully
advanced as a therapeutic in developing markets or that the
results of studies in such markets could be used to advance or
broaden the regulatory or commercialization activities of
Generx in the U.S. or other markets; that the ASPIRE clinical
study will be successful or will lead to approval of Generx by
the Russian Health Authority for marketing and sales in Russia
or lead to approvals in other countries of the Commonwealth of
Independent States; that additional clinical evidence regarding
the safety and effectiveness of Generx that might be obtained
in Russia would be useful for optimizing and broadening
commercial development pathways in other industrialized
countries; that our products or product candidates will not be
unfavorably compared to competitive products that may be
regarded as safer, more effective, easier to use or less
expensive; that FDA or other regulatory clearances or other
certifications, or other commercialization efforts will be
successful or will effectively enhance our businesses or their
market value; that our products or product candidates will
prove to be sufficiently safe and effective after introduction
into a broader patient population; or that third parties on
whom we depend will perform as anticipated.

Actual results may also differ substantially from those
described in or contemplated by this press release due to risks
and uncertainties that exist in our operations and business
environment, including, without limitation, risks and
uncertainties that are inherent in the development of complex
biologics and in the conduct of human clinical trials,
including the timing, costs and outcomes of such trials, our
ability to obtain necessary funding, regulatory approvals and
expected qualifications, our dependence upon proprietary
technology, our history of operating losses and accumulated
deficits, our reliance on collaborative relationships and
critical personnel, and current and future competition, as well
as other risks described from time to time in filings we make
with the Securities and Exchange Commission.  We undertake
no obligation to release publicly the results of any revisions
to these forward-looking statements to reflect events or
circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc.  All rights
reserved.
For Terms of Use Privacy Policy, please
visit www.cardiumthx.com.
Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™,
Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™,
Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™,
D-Sorb™, Neo-Energy™, Neo-Carb Bloc™, Nutra-Apps™ are
trademarks of Cardium Therapeutics, Inc. or Tissue Repair
Company.
(Other trademarks belong to their
respective owners)

Excerpt from:
Cardium Presents New Generx Findings at 2012 Annual Gene and Cell Therapy Forum

Link:
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and …

www.youtube.com/watch?v=2IXy1xzECmI

See the article here:
Gene Therapy: Dr. Zehhr – Video

The key is that you have to have credentials. You will need to get certified from an organization so that you can take part in this job market. This is why you should find a site that provides you with the training if you do not already have it. If you have worked at medical coding and billing jobs in the past, then you may already be certified to work from home with these positions.

The thing that you should remember is that if you are working with people’s medical records, this is a very trusted position to be in. You need to keep things confidential, and the medical office needs to trust that you are going to be able to do this. That is why you have to be certified before you can do medical coding and billing jobs from home.

Working from home has many benefits. You will be able to save money because you will not need to drive to work every day. Furthermore, you will not have to deal with morning traffic or other co-workers who may not be very pleasant. This is why you should make sure to do as much as you can to be able to work from home.

The best thing about working from home is the fact that you can spend time with your kids and family. You can work with medical coding and billing jobs and spend as much time as you want with your kids, and this can be a great feeling. You just have to get certified with the proper training.

There are plenty of sites online that can provide you with a list of medical billing and coding jobs that you can look through. You will see that they will allow you to take training sometimes as well, which means that you can get certified right over the internet as long as you have the time to study. This can be a great feeling as it allows you to have ultimate control over your life, and who could ask for more than that?

Source:
http://www.bamclinic.org/feeds/posts/default?alt=rss